Edgewise Therapeutics (EWTX) closed at $45.82 on November 12, 2026, down 3.7% from the previous close, on volume of 1,018,157 shares (30-day average 1,615,242).
Data as of November 12, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 13, 2026 | Put Diagonal Ratio Spread | 16-Oct-26 35[1468x]|20-Nov-26 30[1463x] P | 5,862 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 11, 2026. See the 10 largest for 30, 60 and 90 days
/C O R R E C T I O N - Edgewise Therapeutics/
PRNewswire (Mon, 9-Nov 11:42 AM ET)
Edgewise Therapeutics to Participate in Upcoming Investor Conferences
PRNewswire (Mon, 9-Nov 8:00 AM ET)
Edgewise Therapeutics’ Buy Rating Reaffirmed on Encouraging EDG-7500 Data and $57 Price Target
TipRanks (Mon, 9-Nov 7:35 AM ET)
Market Chameleon (Thu, 5-Nov 3:53 AM ET)
PRNewswire (Thu, 5-Nov 8:00 AM ET)
Edgewise Therapeutics Reports Third Quarter 2026 Financial Results
PRNewswire (Wed, 4-Nov 4:01 PM ET)
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
PRNewswire (Mon, 2-Nov 8:00 AM ET)
Edgewise Therapeutics Doses First Patient in Phase 2 EQUINOX-HFpEF Trial of EDG-15400
PRNewswire (Thu, 8-Oct 8:01 AM ET)
PRNewswire (Tue, 22-Sep 7:00 AM ET)
PRNewswire (Mon, 24-Aug 8:01 AM ET)
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.
Edgewise Therapeutics trades on the NASDAQ stock market under the symbol EWTX.
As of November 12, 2026, EWTX stock price declined to $45.82 with 1,018,157 million shares trading.
EWTX has a beta of 0.63, meaning it tends to be less sensitive to market movements. EWTX has a correlation of 0.02 to the broad based SPY ETF.
EWTX has a market cap of $5.02 billion. This is considered a Mid Cap stock.
Last quarter Edgewise Therapeutics reported $0 in Revenue and -$.19 earnings per share. This fell short of revenue expectation by $-119 million and missed earnings estimates by -$2.09.
In the last 3 years, EWTX traded as high as $48.78 and as low as $5.34.
The top ETF exchange traded funds that EWTX belongs to (by Net Assets): VTI, IWM, VXF, IWO, IBB.
EWTX has outperformed the market in the last year with a price return of +113.3% while the SPY ETF gained +12.0%. EWTX has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +3.4% and +13.2%, respectively, while the SPY returned -1.5% and -2.0%, respectively.
EWTX support price is $45.60 and resistance is $49.54 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that EWTX shares will trade within this expected range on the day.
